Chronic Angle-closure Glaucoma Clinical Trial
Official title:
A Prospective Study to Assess the Hypotensive Efficacy of Rho-Kinase Inhibitor AR-12286 Ophthalmic Solution 0.5% and 0.7% in Patients With Chronic Angle-closure Glaucoma
To evaluate the ocular hypotensive efficacy of Rho kinase Inhibitor (AR-12286 0.5% and 0.7%)
ophthalmic solutions in patients diagnosed with chronic angle-closure glaucoma treated for 6
months.
Secondary Outcome
Secondary objectives are:
1. To evaluate the early effect of Rho kinase Inhibitor (AR-12286) in reducing intraocular
pressure (IOP).
2. To evaluate the long term effect of the drug on IOP.
3. To determine if AR-12286 can be used as directed therapy for CACG, reducing or
eliminating the structural blockage of the trabecular meshwork that leads to
development of elevated IOP.
n/a
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment